A Phase 1/2 interventional study of MTP-131 in Diabetic Macular Edema and Age-related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-10-26.
Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.
Among the 276 studies in Macular Edema with a site in United States, this one is the 168th largest by enrollment of the 244 interventional ones that give a count, is one of 15 that started in 2014, is one of 31 in phase 1/2, and was the 146th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Kodiak Sciences Inc · Sites in United States, Argentina
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 101 · Phase 3 57 · Phase 4 33
First in 1992; this study’s year is marked. 15 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 45 across the 244 interventional studies, 60 across the 30 observational. Of the 222 that completed or were terminated, 130 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 276 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Edema with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957080Phase 3EyeBiotech Ltd.A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | 2027-01-11 |
| NCT06996080Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 2027-02 |
| NCT06990399Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 2027-04 |
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 276 studies in Macular Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a day in subjects with Diabetic Macular Edema and Age-Related Macular Degeneration.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's enrollment of 20 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General:
DME Treatment Group:
AMD Treatment Group:
Exclusion Criteria:
General:
Ocular Conditions:
Ocular hypertension or glaucoma, dry eye, and any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
Drug: MTP-131
MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
Drug: MTP-131
Incidence and severity of systemic and ocular adverse events
Time frame: From Baseline to Day 28
Change from Baseline in vital sign measurements
Time frame: From Baseline to Day 28
Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale
Time frame: From Baseline to Day 28
Change from Baseline in slit lamp examinations
Time frame: From Baseline to Day 28
Change from Baseline in intraocular pressure
Time frame: From Baseline to Day 28
Change from Baseline in dilated fundoscopic examinations
Time frame: From Baseline to Day 28
Change from Baseline in central subfield thickness
Time frame: From Baseline to Day 28
Change in central subfield thickness
Diabetic Macular Edema (DME) subjects only
Time frame: From Baseline to Day 28
Change from Baseline in widefield angiography
Diabetic Macular Edema (DME) subjects only
Time frame: From Baseline to Day 28
Change from Baseline in fundus autofluorescence pattern including the occurrence of and aggregate size of areas of macular atrophy
Age-Related Macular Degeneration (AMD) subjects only
Time frame: From Baseline to Day 28
Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale
All subjects
Time frame: From baseline to Day 28
The record gives a start of Nov 2014, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →